{
    "organizations": [],
    "uuid": "d73f4895b73fb02c8a61bbdd6478652073f3003a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-arrowhead-receives-regulatory-clea/brief-arrowhead-receives-regulatory-clearance-to-begin-phase-1-study-of-aro-aat-for-treatment-of-alpha-1-liver-disease-idUSFWN1QC0UY",
    "ord_in_thread": 0,
    "title": "BRIEF-Arrowhead Receives Regulatory Clearance To Begin Phase 1 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 22 (Reuters) - Arrowhead Pharmaceuticals Inc:\n* ARROWHEAD RECEIVES REGULATORY CLEARANCE TO BEGIN PHASE 1 STUDY OF ARO-AAT FOR TREATMENT OF ALPHA-1 LIVER DISEASE\n* ARROWHEAD PHARMACEUTICALS - ANTICIPATES DOSING IN PHASE 1 STUDY WILL BEGIN AROUND END OF MARCH Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-22T20:38:00.000+02:00",
    "crawled": "2018-02-23T15:42:10.011+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "arrowhead",
        "pharmaceutical",
        "inc",
        "arrowhead",
        "receives",
        "regulatory",
        "clearance",
        "begin",
        "phase",
        "study",
        "treatment",
        "liver",
        "disease",
        "arrowhead",
        "pharmaceutical",
        "anticipates",
        "dosing",
        "phase",
        "study",
        "begin",
        "around",
        "end",
        "march",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}